Entecavir, Lamivudine Compared for Preventing Hep B Reactivation in Diffuse Large B-Cell Lymphoma

This article originally appeared here.
Entecavir, Lamivudine Compared
Entecavir, Lamivudine Compared

(HealthDay News) — Entecavir is more efficacious than lamivudine for preventing hepatitis B virus (HBV) reactivation among patients who are seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy treatment. These findings have been published in the Dec. 17 issue of the Journal of the American Medical Association.

He Huang, MD, from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues compared the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy treatment. Patients were seropositive for the hepatitis B surface antigen and had normal liver function. They were randomized to daily 0.5mg entecavir (61 patients) or 100mg lamivudine (60 patients) beginning one week before R-CHOP initiation.

The researchers found that the incidence of HBV-related hepatitis was significantly lower in the entecavir group than in the lamivudine group (0 vs. 13.3%; P=0.003). The incidence of HBV reactivation was also significantly lower in the entecavir group (6.6 vs. 30.0%; P=0.001), as was chemotherapy disruption (1.6 vs. 18.3%; P=0.002).

"If replicated, these findings support the use of entecavir in these patients," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)